Quercetin immunity research surges, mapping review finds 12 thematic clustersMapping the growth of quercetin research for immune health
Frontiers in MedicinePublished September 12, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Recognize this as a mapping review of research trends, not clinical efficacy data for quercetin.
This systematic mapping review characterized the publication trajectory, knowledge structure, and emerging frontiers of quercetin-immunity research. The authors analyzed 10,619 unique publications and found that 6,440 (60.65% of the dataset) appeared during 2021 to 2025, indicating rapid growth in this field.
The knowledge core included stable mechanistic terms such as oxidative stress, inflammation, signal transduction, apoptosis, NF-kB, TNF, IL-6, and IL-1beta. Latent Dirichlet allocation topic modeling identified 12 topics, including inflammatory signaling, systems pharmacology, senescence, oxidative organ injury, tumor immunity, neuroinflammation and ferroptosis, infection and intestinal inflammation, allergy and mast-cell activation, delivery systems, and bioavailability.
Emerging frontiers highlighted by the authors included molecular docking, network pharmacology, protein-protein interaction, Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology analyses, ferroptosis, macrophage polarization, and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling.
The authors noted that mapping-level assessment indicated low-to-moderate residual risk. No safety data, adverse events, or tolerability outcomes were reported. Funding and conflicts of interest were not reported. The authors emphasized that future studies should prioritize physiologically attainable exposures, active metabolites, immune-cell specificity, disease-stage effects, multi-omics validation, and clinically relevant dosing.
This review maps the state of research rather than clinical efficacy. Clinicians should interpret these findings as a description of the scientific literature, not as evidence supporting quercetin use for any inflammatory, oncologic, allergic, or infectious condition.
How this fits prior evidence
This mapping review addresses a gap in prior coverage by characterizing the quercetin-immunity research landscape, whereas prior items focused on clinical interventions such as play interventions for anxiety in children with cancer, nurse-coordinated immune checkpoint inhibitor safety monitoring, eREACH genetic counseling, and integrative medicine training needs. It does not confirm or contrast with those clinical findings, as it reports no patient outcomes or intervention effects. Instead, it provides a bibliometric overview showing rapid publication growth and identifies mechanistic themes like ferroptosis and Nrf2 signaling, which may inform future hypothesis-driven studies but does not alter current clinical practice.
Scientists are looking closer at how certain compounds interact with our immune systems. A large mapping review of over 10,000 publications analyzed the research landscape for quercetin, a compound often studied for its role in managing inflammation, allergies, and infections.
The review found that research in this area is growing rapidly, with over 6,000 papers published in just the last few years. Researchers identified a core of stable topics, such as how the compound affects oxidative stress and specific inflammatory signals. They also identified 12 distinct areas of study, ranging from how the body handles organ injury to how it responds to allergens.
While the research is expanding into complex areas like protein interactions and cell signaling, it is important to remember that this was a mapping of existing literature. It is not a clinical trial, so it does not provide evidence on how well quercetin works as a treatment for any specific person. Experts suggest that future studies need to focus more on practical dosing and how the body actually processes the compound to be more useful in a clinical setting.
What this means for you:
Research into quercetin is expanding rapidly, covering diverse areas like inflammation, allergy, and infection.
Common questions
What does this study say about quercetin's effectiveness?
This was a mapping review of 10,619 publications, not a clinical trial. It describes the current state of scientific research and the topics scientists are studying, rather than proving how well quercetin works as a treatment for any specific medical condition.
What specific conditions are being studied in relation to quercetin?
The research covers several different areas, including inflammatory diseases, cancer, allergy, and infection. The study identified 12 specific topics, such as neuroinflammation, intestinal inflammation, and mast-cell activation.
Is there any information on the safety of quercetin?
The study did not report on any specific adverse events, safety signals, or tolerability. Because this was a review of research trends and not a clinical trial, it does not provide information on the safety of using quercetin.
ObjectiveQuercetin is a representative flavonol at the interface of natural-product pharmacology, nutrition, and immune regulation, with reported anti-inflammatory, antioxidant, antiviral, antiallergic, antitumor, and metabolic activities. This systematic mapping review aimed to characterize the publication trajectory, knowledge structure, latent themes, and emerging frontiers of quercetin-immunity research from 2006 to 2025.MethodsEnglish-language original articles and reviews published from January 1, 2006 to December 31, 2025 were retrieved from the Web of Science Core Collection, Scopus, and PubMed. Following harmonized eligibility reassessment, field standardization, and cross-database deduplication, bibliometric analysis, science mapping, keyword co-occurrence, temporal and burst analyses, thematic maturity assessment, citation and co-citation analyses, and latent Dirichlet allocation (LDA) topic modeling were integrated to examine the explicit and latent knowledge structures. Mapping-level risk of bias was qualitatively assessed.ResultsThe searches yielded 15,938 raw records, of which 10,619 unique publications were included, comprising 7,754 original articles and 2,865 reviews. Of these, 6,440 publications appeared during 2021–2025, accounting for 60.65% of the dataset and demonstrating rapid growth. The field spanned natural products, pharmacology, molecular biology, nutrition, and immunology, with China, India, and the United States as the leading contributors. Stable mechanistic terms included oxidative stress, inflammation, signal transduction, apoptosis, NF-κB, TNF, IL-6, and IL-1β, indicating a knowledge core centered on inflammatory cytokine networks, redox homeostasis, transcriptional regulation, and cell-fate control. LDA resolved 12 topics spanning inflammatory signaling, systems pharmacology, senescence, oxidative organ injury, tumor immunity, neuroinflammation and ferroptosis, infection and intestinal inflammation, allergy and mast-cell activation, delivery systems, and bioavailability. Recent frontiers included molecular docking, network pharmacology, protein–protein interaction, Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology analyses, ferroptosis, macrophage polarization, and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling, indicating a shift toward multi-target, systems-level mechanistic investigation. The mapping-level assessment indicated low-to-moderate residual risk.ConclusionQuercetin-immunity research has evolved from broad anti-inflammatory studies into an interdisciplinary field focused on inflammatory signaling, oxidative stress, immune-cell function, disease-specific immunopathology, and systems pharmacology. Future studies should prioritize physiologically attainable exposures, active metabolites, immune-cell specificity, disease-stage effects, multi-omics validation, and clinically relevant dosing.
